Moleculin Biotech, Inc. MBRX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +138.67%
- 1 year
- -30.09%
- Open
- 8.80
- Prev close
- 8.72
- Mkt cap
- 8.05M
- Vol
- 31.72K
- Avg vol
- 72.98K
- EPS
- 179.60
- P/E
- 0.04
- Div yield
- 0.00%
More statistics
- Low
- 7.90
- High
- 9.00
- Forward P/E
- -0.29
- Beta
- 0.00
- Short ratio
- 0.36
- Inst. own
- 15.34%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 22, 2024
- 50-d avg
- 2.49
- 200-d avg
- 3.26
- 1y target
- 18.00
5D chart
Signals (101)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:10 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:10 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 4:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:05 PM | 3 days ago |
| RSI: Overbought | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| RSI: Oversold | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
News
-
2 days ago benzinga.com
Moleculin Biotech Completes Participant Dosing In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia
Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company") today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in…
2 days ago globenewswire.com
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)
5 days ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
1 week ago globenewswire.com
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Access the Moleculin CEO Corner here
-
2 weeks ago benzinga.com
Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20
Filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The…
2 weeks ago globenewswire.com
Moleculin Announces Reverse Stock Split
HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate…
3 weeks ago globenewswire.com
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New…
-
1 month ago benzinga.com
Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia
Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin…
1 month ago globenewswire.com
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal…
1 month ago globenewswire.com
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
-
1 month ago benzinga.com
Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside…
1 month ago globenewswire.com
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin's antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside…
1 month ago globenewswire.com
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
1 month ago benzinga.com
Dow Surges Over 200 Points; Chicago Fed Activity Index Falls In August
U.S. stocks rose Monday, led by the Dow’s 200-point gain; communication shares climbed, energy fell, while oil dropped and Greenland stocks surged.
1 month ago globenewswire.com
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap…
1 month ago globenewswire.com
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th…
1 month ago defenseworld.net
Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell?
Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $1.21 and traded as low as…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.
2 months ago globenewswire.com
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
- Video webcast now available here
2 months ago zacks.com
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-
2 months ago benzinga.com
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of…
2 months ago globenewswire.com
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
3 months ago benzinga.com
Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
3 months ago globenewswire.com
Moleculin Announces Pricing of $9.3 Million Public Offering
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of…
3 months ago globenewswire.com
Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure - a setting in which published salvage remission rates are approximately 13% and median survival approximately 2. 4 months - shows no adverse impact on blinded composite…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's regular session. The market value of their outstanding shares is at $1.4 million. SciSparc (NASDAQ:SPRC)…
-
3 months ago benzinga.com
Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor Segment
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What
3 months ago globenewswire.com
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief…
4 months ago benzinga.com
Why is Moleculin Stock Falling Today?
Moleculin reports interim Phase 2/3 trial data as Annamycin shows higher remission rates than control in relapsed or refractory acute myeloid leukemia
-
4 months ago benzinga.com
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular session. Atlantic International (NASDAQ:ATLN) stock rose 143.31% to $1.07. The market value of their…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million. Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to…
-
5 months ago benzinga.com
Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid Leukemia
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What…
-
5 months ago benzinga.com
Moleculin Biotech Announces That New Data Further Reinforcing The Differentiated Cardiac Safety Profile Of Its Lead Drug Candidate, Annamycin, Was Presented At The American Society Of Clinical Oncology Annual Meeting
The poster presentation, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," highlighted findings from a pooled analysis across five completed clinical…
-
5 months ago benzinga.com
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses…
5 months ago benzinga.com
Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding
Moleculin Biotech nears first MIRACLE trial data unblinding as Annamycin shows higher remission rates in relapsed AML patients.
-
5 months ago benzinga.com
Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30,…
-
5 months ago benzinga.com
Moleculin Biotech Announces Publication Of An Abstract At The European Hematology Association Congress That Highlights The Cardiac Safety Profile Of Annamycin
The abstract titled, "Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposure: Implications for Relapsed/Refractory AML," will highlight pooled cardiac safety findings from five…
-
5 months ago benzinga.com
Moleculin Biotech Announces Significant Advancement In IP Portfolio With Issuance Of Hong Kong Patent Covering Proprietary Method Of Reconstituting Liposomal Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data ReleaseHOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the…
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Moleculin Biotech, Maintains $22 Price Target
HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $22 price target.
-
7 months ago benzinga.com
Moleculin Biotech Announces 45th Enrollee In Phase2B/3 Trial For Annamycin Plus Cytarabine As A Treatment For Relapsed Or Refractory Acute Myeloid Leukemia
This milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point…
-
7 months ago benzinga.com
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over…
8 months ago benzinga.com
Crude Oil Gains 2%; Walmart Posts Upbeat Earnings
Crude Oil Gains 2%; Walmart Posts Upbeat Earnings